Imatimib Mesylate
AAAT1955
Phase 1 small_molecule active
Quick answer
Imatimib Mesylate for Lymphangioleiomyomatosis (LAM) is a Phase 1 program (small_molecule) at United Therapeutics Europe Ltd with 1 ClinicalTrials.gov record(s).
Program details
- Company
- United Therapeutics Europe Ltd
- Indication
- Lymphangioleiomyomatosis (LAM)
- Phase
- Phase 1
- Modality
- small_molecule
- Status
- active